Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain

By Imanaka Keiichiro   Tominaga Yushin   Etropolski Mila   van Hove Ilse   Ohsaka Masaki   Wanibe Mikio   Hirose Keiichiro   Matsumura Taka  

Current Medical Research and Opinion, Vol. 29, Iss. 10, 2013-10 ,pp. : 1399-1409

Informa Healthcare

Access to resources Recommend Favorite

Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open‐label Continuation Arm of a Randomized Phase 3b Study

By  

PAIN PRACTICE, Vol. 15, Iss. 5, 2015-06 ,pp. : 471-486

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double‐blind, Phase 3b Study

By  

PAIN PRACTICE, Vol. 15, Iss. 5, 2015-06 ,pp. : 455-470

John Wiley & Sons Inc

Access to resources Recommend Favorite

Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?

By Candiotti Keith A.   Gitlin Melvin C.  

Current Medical Research and Opinion, Vol. 26, Iss. 7, 2010-07 ,pp. : 1677-1684

Informa Healthcare

Access to resources Recommend Favorite

Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules

By Nicholson Bruce   Ross Edgar   Weil Arnold   Sasaki John   Sacks Gerald  

Current Medical Research and Opinion, Vol. 22, Iss. 3, 2006-03 ,pp. : 539-550

Informa Healthcare

Access to resources Recommend Favorite